Table 3.
Main findings of the included studies about 18F-PSMA-1007 PET/CT in staging patients with prostate cancer.
| Authors | Reference Standard | Patient-Based Analysis | Lesion-Based Analysis | Change of Management by Using PET/CT | Study Quality * | Study Summary | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sensitivity | Specificity | Accuracy | Sensitivity | Specificity | Accuracy | |||||
| Anttinen et al. [24] *** | The reference standard diagnosis was defined using all available information accrued during at least 12 months of clinical follow-up | 86–95% | 76–90% | 80–89% | 72–86% | NR | NR | 14/79 (18%) | fair | 18F-PSMA-1007 PET/CT has superior sensitivity and the highest inter-reader agreement compared with standard and advanced imaging modalities for PCa staging. |
| Giesel et al. [25] | NR | 100% | 100% | 100% | 95% | 100% | NR | NR | fair | 18F-PSMA-1007 PET/CT has high sensitivity in detecting PCa lesions. |
| Giesel et al. [26] | NR | 100% | NR | NR | NR | NR | NR | NR | fair | Excellent imaging quality and concordance are achieved with both 18F-DCFPyL and 18F-PSMA-1007. |
| Hong et al. [27] *** | Histology | NR | NR | NR | NR | NR | NR | NR | fair | There is a significant positive correlation between PSA level/GS and SUVmax at 18F-PSMA-1007 PET/CT. |
| Kesch et al. [28] | Histology and mpMRI | 100% | NR | NR | 93% | 92% | 93% | NR | fair | Comparison with histopathology demonstrates that 18F-PSMA-1007 PET/CT is promising for accurate local staging of PCa. |
| Kuten et al. [29] | Histology | 100% | NR | NR | 100% | 91% | 95% | NR | fair | Both 18F-PSMA-1007 and 68Ga-PSMA-11 PET/CT may identify all dominant prostatic lesions in patients with PCa at staging. 18F-PSMA-1007 may detect additional lesions of limited clinical relevance. |
| Privé et al. [30] *** | Histology and mpMRI | 98% | NR | NR | NR | NR | NR | NR | fair | Dual imaging with mpMRI and 18F-PSMA-1007 PET/CT may improve staging of primary PCa. Higher PCa aggressiveness was associated with higher SUVmax at 18F-PSMA-1007 PET/CT. |
| Sprute et al. [31] *** | Histology | 74% ** | 99% ** | NR | 71% ** | 99.5% ** | NR | NR | fair | 18F-PSMA-1007 PET/CT reliably detects PCa lymph nodal metastases with very high specificity. |
Legend: * = according to the National Institute of Health (NIH) quality assessment tools; ** = lymph nodal lesions only; *** = studies with larger patient population; GS = Gleason score; mpMRI = multi-parametric magnetic resonance imaging; NR = not reported; PCa = prostate cancer; PET/CT = positron emission tomography/computed tomography; PSA = prostate specific antigen; PSMA = prostate specific membrane antigen; SUVmax = standardized uptake value.